{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+Fiasp&page=2", "query": { "intervention": "Insulin Fiasp", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 180, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+Fiasp&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Insulin+Fiasp&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T03:58:03.359Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02443402", "title": "Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Regular Human Insulin", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Supplemental insulin (Insulin lispro)", "type": "DRUG" }, { "name": "Supplemental insulin (Insulin aspart)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 68, "start_date": "2016-01", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-02-06", "last_synced_at": "2026-10-01T03:58:03.359Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02443402" }, { "nct_id": "NCT02182895", "title": "Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "18 Years to 110 Years" }, "enrollment_count": 72, "start_date": "2014-07", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2017-06-23", "last_synced_at": "2026-10-01T03:58:03.359Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02182895" }, { "nct_id": "NCT01682902", "title": "A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Faster-acting insulin aspart", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2012-09", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2017-01-09", "last_synced_at": "2026-10-01T03:58:03.359Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01682902" }, { "nct_id": "NCT00417989", "title": "Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "MiniMed Paradigm REAL-Time System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medtronic MiniMed, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "7 Years to 70 Years" }, "enrollment_count": 485, "start_date": "2007-01", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2018-05-23", "last_synced_at": "2026-10-01T03:58:03.359Z", "location_count": 26, "location_summary": "La Jolla, California • Orange, California • Boulder, Colorado + 23 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Boulder", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00417989" }, { "nct_id": "NCT00612040", "title": "Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "insulin degludec", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 178, "start_date": "2008-01", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-10-01T03:58:03.359Z", "location_count": 9, "location_summary": "Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more", "locations": [ { "city": "Walnut Creek", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Hyattsville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612040" }, { "nct_id": "NCT01814137", "title": "A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec/insulin aspart", "type": "DRUG" }, { "name": "insulin degludec", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2013-03", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-10-01T03:58:03.359Z", "location_count": 26, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 22 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01814137" }, { "nct_id": "NCT01109316", "title": "Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Insulin lispro 2 day reservoir in-use", "type": "DRUG" }, { "name": "Insulin lispro 6 day reservoir in-use", "type": "DRUG" }, { "name": "Insulin aspart 6 day reservoir in-use", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 132, "start_date": "2010-04", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2019-03-27", "last_synced_at": "2026-10-01T03:58:03.359Z", "location_count": 11, "location_summary": "Concord, California • Aurora, Colorado • Hollywood, Florida + 8 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Idaho Falls", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT01109316" }, { "nct_id": "NCT05946798", "title": "Role of NADPH Oxidase in Microvascular Dysfunction Following GDM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Gestational Diabetes", "Oxidative Stress", "Vascular Endothelial Function" ], "interventions": [ { "name": "Acetylcholine", "type": "DRUG" }, { "name": "Insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anna Stanhewicz, PhD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 40, "start_date": "2023-08-30", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-01T03:58:03.359Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05946798" }, { "nct_id": "NCT02556918", "title": "Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hyperglycemia" ], "interventions": [ { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Regular Human Insulin", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Supplemental insulin (Insulin lispro)", "type": "DRUG" }, { "name": "Supplemental insulin (Insulin aspart)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 202, "start_date": "2016-01", "completion_date": "2018-11-06", "has_results": true, "last_update_posted_date": "2019-12-23", "last_synced_at": "2026-10-01T03:58:03.359Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02556918" }, { "nct_id": "NCT00442767", "title": "Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin", "type": "DRUG" }, { "name": "Pramlintide + Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Years to 21 Years" }, "enrollment_count": 8, "start_date": "2007-02", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2018-07-10", "last_synced_at": "2026-10-01T03:58:03.359Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00442767" } ] }